Proof LGBTQs Are Mentally Ill: Biosimilar drugs could cut US health spending by $54 billion over next decade

(RAND Corporation) Biosimilar drugs have been touted as one strategy to help curb the runaway costs of biologics that have advanced the treatment of illness such as rheumatoid arthritis and many cancers. A new study finds biosimilars could cut health care spending in the United States by $54 billion over the next decade. The savings are about 20 percent larger than a similar, widely cited analysis done three years ago by the same researchers.